Convelo Therapeutics, Inc

Convelo Therapeutics is developing a new class of medicines that unlock the regenerative capacity of the central nervous system. Convelo is pioneering approaches to regenerate the protective myelin coating around nerve cells that is lost in a wide array of neurological diseases including multiple sclerosis, pediatric leukodystrophies, traumatic injury and age-related pathologies such as Alzheimers. Convelo has identified key biological targets and a pipeline of drug candidates to provide novel and meaningful solutions for patients and their families

Convelo therapeutics, inc operates in the Biotechnology research industry.

Convelo therapeutics, inc's revenue is 11m - 100m

Convelo therapeutics, inc has 11 - 50 employees.